New England Capital Financial Advisors’s Mereo BioPharma MREO Stock Holding History

New England Capital Financial Advisors’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$96	Hold	300	–	–	﹤0.01%	419
2026 Q1	$99	Hold	300	–	–	﹤0.01%	413
2025 Q4	$126	Hold	300	–	–	﹤0.01%	407
2025 Q3	$618	Hold	300	–	–	﹤0.01%	381
2025 Q2	$813	Hold	300	–	–	﹤0.01%	370
2025 Q1	$675	Hold	300	–	–	﹤0.01%	346
2024 Q4	$1.05K	Hold	300	–	–	﹤0.01%	353
2024 Q3	$1.23K	Hold	300	–	–	﹤0.01%	338
2024 Q2	$1.08K	Hold	300	–	–	﹤0.01%	339
2024 Q1	$990	Hold	300	–	–	﹤0.01%	338
2023 Q4	$693	Hold	300	–	–	﹤0.01%	356
2023 Q3	$387	Hold	300	–	–	﹤0.01%	366
2023 Q2	$396	Hold	300	–	–	﹤0.01%	362
2023 Q1	$213	Hold	300	–	–	﹤0.01%	416
2022 Q4	$291	Buy	+300	New	+$246	﹤0.01%	408

Other funds holding MREO

SWP

Significant Wealth Partners Cary, Illinois $92.4M AUM 9.22% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

APA

Astoria Portfolio Advisors New York $593M AUM 28.97% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New England Capital Financial Advisors's MREO Position: Q2 2026 in Review

New England Capital Financial Advisors held its Mereo BioPharma (MREO) position steady in Q2 2026 at 300 shares worth $96. The position accounts for ﹤0.01% of the portfolio, ranked #419.

New England Capital Financial Advisors first reported a position in MREO in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.23K in Q3 2024. 9 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

New England Capital Financial Advisors held 300 shares of Mereo BioPharma worth $96 as of Q2 2026.
New England Capital Financial Advisors left its Mereo BioPharma share count unchanged in Q2 2026.
Mereo BioPharma made up ﹤0.01% of New England Capital Financial Advisors's portfolio in Q2 2026, its #419 holding.
New England Capital Financial Advisors first reported a position in Mereo BioPharma in Q4 2022 and has held it in 15 quarters since.
New England Capital Financial Advisors's Mereo BioPharma position peaked at $1.23K in Q3 2024.
9 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on New England Capital Financial Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.